AZ China Growth Pops Again But Clouds Loom

Lying underneath AstraZeneca’s stellar quarter were the growth engines of emerging markets and China, where novel drugs, especially in oncology, delivered. But mounting pricing pressures and a massive new centralized bidding process are clouds on the horizon.

China flag with arrow graph going up showing strong economy and shares rise. Profit and success. Isolated vector illustration.
China Growth For AstraZeneca But Uncertainty Ahead? • Source: Shutterstock

A strategic bet on oncology and a focused strategy in emerging markets, especially China, have paid off for AstraZeneca PLC.

The UK-based company's fourth quarter showed growth in China was particularly strong, driven by new drugs to treat cancer. The...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip